0001458511-17-000003.txt : 20171018
0001458511-17-000003.hdr.sgml : 20171018
20171018151927
ACCESSION NUMBER: 0001458511-17-000003
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20171018
DATE AS OF CHANGE: 20171018
EFFECTIVENESS DATE: 20171018
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellipharmaceutics International Inc.
CENTRAL INDEX KEY: 0001474835
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1130
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-296978
FILM NUMBER: 171142589
BUSINESS ADDRESS:
STREET 1: 30 WORCESTER ROAD
CITY: TORONTO
STATE: A6
ZIP: M9W 5X2
BUSINESS PHONE: 416-798-3001
MAIL ADDRESS:
STREET 1: 30 WORCESTER ROAD
CITY: TORONTO
STATE: A6
ZIP: M9W 5X2
FORMER COMPANY:
FORMER CONFORMED NAME: IntelliPharmaCeutics International Inc.
DATE OF NAME CHANGE: 20091020
D
1
primary_doc.xml
X0708
D
LIVE
0001474835
Intellipharmaceutics International Inc.
30 WORCESTER ROAD
TORONTO
A6
ONTARIO, CANADA
M9W 5X2
416-798-3001
ONTARIO, CANADA
IntelliPharmaCeutics International Inc.
Corporation
true
Isa
Odidi
30 Worcester Road
Toronto
A6
ONTARIO, CANADA
M9W 5X2
Executive Officer
Director
Amina
Odidi
30 Worcester Road
Toronto
A6
ONTARIO, CANADA
M9W 5X2
Executive Officer
Director
Eldon
R.
Smith
30 Worcester Road
Toronto
A6
ONTARIO, CANADA
M9W 5X2
Director
Kenneth
Keirstead
30 Worcester Road
Toronto
A6
ONTARIO, CANADA
M9W 5X2
Director
Bahadur
Madhani
30 Worcester Road
Toronto
A6
ONTARIO, CANADA
M9W 5X2
Director
Andrew
Patient
30 Worcester Road
Toronto
A6
ONTARIO, CANADA
M9W 5X2
Executive Officer
Michael
Campbell
30 Worcester Road
Toronto
A6
ONTARIO, CANADA
M9W 5X2
Executive Officer
Pharmaceuticals
$1,000,001 - $5,000,000
- 06b
false
2017-10-11
false
true
true
false
0
H.C. Wainwright Co., LLC
375
None
None
430 Park Avenue
4th Floor
New York
NY
NEW YORK
10022
NJ
NEW JERSEY
NY
NEW YORK
false
2522728
2522728
0
Represents the aggregate warrant exercise price for the warrants covered by this Form D, which were issued in a private placement ("PP") conducted concurrently with a registered direct offering ("RDO") of common shares not the subject of this Form D.
false
6
280000
0
H.C. Wainwright Co., LLC ("Wainwright") received the above sales commissions, and $65,000 in expense reimbursements in connection with the RDO and the PP of the warrants. Wainwright also received warrants to purchase an aggregate of 181,818 common shares.
0
false
Intellipharmaceutics International Inc.
Andrew Patient
Andrew Patient
CFO
2017-10-18